Table 3 Comparisons of the therapeutic effects between different groups.
Outcome measures | VA1, n = 11 | VA2, n = 11 | VA3, n = 13 | SA, n = 11 | P value * | WT, n = 16 | AG, n = 46 | P value ** |
|---|---|---|---|---|---|---|---|---|
Headache intensity Mean (95%CI) | ||||||||
 End of treatment | 3.18 (2.24; 4.12) | 3.73 (2.82; 4.63) | 3.15 (2.31; 3.99) | 4.04 (3.09; 5.00) | 0.351 | 5.72 (4.84; 6.59) | 3.51 (3.10;3.93) | 0.000 |
 End-baseline | −2.27 (−3.55; −0.99) | −1.59 (−2.42; −0.75) | −2.54 (−3.41; −1.66) | −1.14 (−2.80; 0.52) | 0.242 | 0.06 (−0.68; 0.81) | −1.91 (−2.46; −1.37) | 0.000 |
Headache frequency Mean (95%CI) | ||||||||
 End of treatment | 4.18 (2.60; 5.77) | 6.18 (4.13; 8.03) | 4.08 (2.40; 5.76) | 6.45 (3.97; 8.94) | 0.107 | 8.63 (6.14; 11.11) | 5.17 (4.27; 6.08) | 0.012 |
 End-baseline | −1.73 (−3.23; −0.22) | −1.27 (−2.89; 0.35) | −1.46 (−2.83; −0.10) | 0.00 (−2.75; 2.75) | 0.493 | 4.31 (2.26; 6.37) | −1.13 (−1.97; −0.29) | 0.000 |
SAS score Mean (95%CI) | ||||||||
 End of treatment | 39.20 (31.93; 46.48) | 41.77 (36.43; 47.11) | 37.96 (31.68; 44.25) | 38.02 (32.97; 43.08) | 0.745 | 41.64 (37.76; 45.52) | 39.18 (36.46; 41.91) | 0.336 |
 End-baseline | −5.84 (−13.05; 1.37) | −3.50 (−8.91; 1.91) | −8.79 (−15.54; −2.04) | −7.66 (−16.46; 1.14) | 0.670 | −5.17 (−10.07; −0.27) | −6.55 (−9.74; −3.36) | 0.649 |
SDS score Mean (95%CI) | ||||||||
 End of treatment | 41.93 (33.11; 50.75) | 43.86 (36.67; 51.05) | 38.92 (32.31; 45.53) | 37.34 (30.69; 43.98) | 0.520 | 41.25 (35.99; 46.51) | 40.45 (37.14; 43.75) | 0.799 |
 End-baseline | −0.48 (−5.35; 4.40) | −7.00 (−14.72; 0.72) | −4.98 (−10.44; 0.48) | −6.93 (−15.95; 2.09) | 0.432 | −6.09 (−12.61; 0.42) | −4.85 (−7.96; −1.74) | 0.697 |
